Capricor Therapeutics Inc banner

Capricor Therapeutics Inc
NASDAQ:CAPR

Watchlist Manager
Capricor Therapeutics Inc Logo
Capricor Therapeutics Inc
NASDAQ:CAPR
Watchlist
Price: 29.1 USD -6.64% Market Closed
Market Cap: $1.3B

During the last 3 months Capricor Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 1% over this period (open performance analysis).

The last transaction was made on Sep 20, 2024 by Nippon Shinyaku Co Ltd , who bought 15m USD worth of CAPR shares.

Last Transactions:
Nippon Shinyaku Co Ltd
$+15m
Musket David B
$+1.1k
Collier Earl M Jr
$+28.3k
Musket David B
$+14.3k
Auwaerter Paul Gisbert
$+14.2k
Musket David B
$+7.3k
Avat Xavier
$-949.2m
Avat Xavier
$-12.2k
Avat Xavier
$+3.7k
Avat Xavier
$+5.6k
Musket David B
$-106.4k
Musket David B
$-78.9k
Cedars Sinai Medical Center
$+355k
Musket David B
$+7.8k
Manzo Louis
$+3.1k
Cedars Sinai Medical Center
$+100k
Cedars Sinai Medical Center
$+100k
Gershell Leland
$+504
Krasney Karen
$+974.4
Marban Linda
$+2.4k
Bergmann Anthony
$+487.2
Manzo Louis
$+24k
Grasmick Louis J
$+17.1k
Edward St. John, Llc
$+100k
Grasmick Louis J
$+1.9k
Grasmick Louis J
$+557
Marban Linda
$+1.9k
Marban Eduardo
$+1.9k
Marban Linda
$+2.2k
Marban Eduardo
$+2.2k
View All Transactions

During the last 3 months Capricor Therapeutics Inc insiders have not bought any shares, and have not sold any shares. The stock price has dropped by 1% over this period (open performance analysis).

The last transaction was made on Sep 20, 2024 by Nippon Shinyaku Co Ltd , who bought 15m USD worth of CAPR shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Capricor Therapeutics Inc
Insider Trading Chart

Capricor Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Capricor Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Capricor Therapeutics Inc
Glance View

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. The company is headquartered in Beverly Hills, California and currently employs 48 full-time employees. The company went IPO on 2002-06-04. The firm consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The firm is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.

CAPR Intrinsic Value
15.16 USD
Overvaluation 48%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett